Volume 36

Issue 6

Article 14

6-20-2021

Construction of China’s Strategic Science and Technology Forces
from Research and Development of COVID-19 Vaccine
Xinmin ZHANG
China National Center for Biotechnology Development, Beijing 100039, China

Recommended Citation
ZHANG, Xinmin (2021) "Construction of China’s Strategic Science and Technology Forces from Research and Development of COVID-19 Vaccine," Bulletin of Chinese Academy
(Chinese Version): Vol. 36 : Iss. 6 , Article 14.
DOI: https://doi.org/10.16418/j.issn.1000-3045.20210512003
Available at: https://bulletinofcas.researchcommons.org/journal/vol36/iss6/14

This Strategy & Policy Decision Research is brought to you for free and open access by Bulletin of Chinese Academy
of Sciences (Chinese Version). It has been accepted for inclusion in Bulletin of Chinese Academy of Sciences
(Chinese Version) by an authorized editor of Bulletin of Chinese Academy of Sciences (Chinese Version). For more
information, please contact lcyang@cashq.ac.cn, yjwen@cashq.ac.cn.

Construction of China’s Strategic Science and Technology Forces from Research
and Development of COVID-19 Vaccine
Abstract
Strengthening strategic science and technology forces is the key to achieve scientific and technological
self-reliance and self-improvement. China's COVID-19 vaccine research and development has achieved a
stage success and such success has inseparable relationship with the national strategic science and
technology forces. This paper starts from the current situation of COVID-19 vaccine R&D in China and in
the world, further considers and explores the mission positioning, top-level design, and strengthening
methods of China's strategic science and technology forces, and proposes corresponding policy
suggestions on strengthening China's strategic science and technology force, through analyzing the
successful experience of China's COVID-19 vaccine R&D.
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Abstract: Strengthening strategic science and technology forces is the key to achieving scientific and technological
self-reliance and self-improvement. China’s research and development (R&D) of COVID-19 vaccine has achieved a
phased success which has inseparable relationship with the national strategic science and technology forces. This
paper starts from the current situation of COVID-19 vaccine R&D in China and the world, further analyzes the mission positioning, top-level design, and strengthening methods of China’s strategic science and technology forces
regarding the successful experience of China’s COVID-19 vaccine R&D, and finally proposes corresponding policy
suggestions on strengthening China’s strategic science and technology forces. DOI: 10.16418/j.issn.1000-3045.
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A report at the 19th National Congress of the Communist
Party of China (CPC) suggests to strengthen the construction
of innovation system and reinforce strategic science and
technology forces of China. National strategic science and
technology forces embody state will, shoulder state mission,
and stand for national science and technology level.
Strengthening strategic science and technology forces is the
key to achieving scientific and technological self-reliance
and self-improvement [1]. The research and development
(R&D) of COVID-19 vaccine hinges on national strategic
science and technology forces. In light of the status quo of
COVID-19 vaccine R&D, we find it essential to review its
path, experience, and strategies. Attributed to governmental
responsibilities and the exercise of market economy in the
context of global pandemic, China has reaped phased
achievements in COVID-19 vaccine R&D, in which national
strategic science and technology forces play a critical role.
The research on it will shed light on how to improve China’s
strategic science and technology forces.

1
1.1

The R&D status quo of COVID-19 vaccine
Global overview

Vaccine is considered as the most effective and economical means to prevent and control a pandemic. After the outbreak of COVID-19, countries around the world are urgent to
develop safe and effective vaccines as soon as possible.

According to the data released by World Health Organization
(WHO), as of May 25, 2021, a total of 101 COVID-19 vaccines have entered clinic trial stage, including 36 recombinant protein subunit vaccines [including peptide vaccines and
virus-like particle (VLP) vaccines], 26 nuclear acid vaccines
(DNA vaccines and RNA vaccines), 18 viral vector vaccines,
16 inactivated vaccines, and two live attenuated vaccines ①.
So far, 12 COVID-19 vaccines have been registered for being
launched to the market or have been launched to the market
with conditions in many countries. Large-scale vaccination
has been initiated, being an important approach to curbing the
spread of COVID-19.

1.2

China’s overview

China is one of the few countries capable of independently
developing vaccines for the immunization program [2]. In the
face of COVID-19, China took the lead in vaccine development relying on science and technology. China is making
good use of its new system concentrating nationwide efforts
and resources on key undertakings, showing to the world
China’s sharp competitive edge in the global vaccine race. In
January, 2020, China launched R&D projects to tackle
emergence problems including vaccine development. Regarding vaccine development, China has deployed five major
technological lines with 12 selected research teams [3]. As of
April, 2021, a total of 19 vaccines across the country have
been approved for clinical research, covering all the five
technological lines. National Vaccine and Serum Institute,
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Wuhan Institute of Biological Products Co., Ltd., and Sinovac Research & Development Co., Ltd. developed inactivated vaccines, respectively. Academy of Military Medical
Sciences and CanSinoBIO jointly developed an adenovirus
vector vaccine. All of the above vaccines have been approved
for marketing conditionally. The Institute of Microbiology,
Chinese Academy of Sciences (CAS) and Anhui Zhifei
Longcom Biopharmaceutical Co., Ltd. jointly developed a
recombinant COVID-19 vaccine, which was approved domestically for emergency in March, 2021 ①.
The speed from initiation to approval has far outpaced the
regular duration of 5–18 years and surpassed that of 12–18
months in the context of a pandemic [4]. China ranks top in
terms of COVID-19 vaccine quantity, category, and R&D
speed.

2 China’s experience in R&D of COVID-19
vaccine
China’s success in COVID-19 vaccine R&D illustrates
China’s new system concentrating nationwide efforts and
resources in response to emergence, which has built up experience in using science and technology to underpin national
major strategies.

2.1 Coordinated arrangement facilitates the concentration of nationwide efforts and resources
COVID-19 vaccine R&D is a typical example showing
how China responds to emergence through a new system
concentrating nationwide efforts and resources on key undertakings. This new system is vital to the success in
COVID-19 vaccine R&D and provides institutional guarantee for the strengthening of strategic science and technology
forces.
(1) The CPC Central Committee makes wise decisions.
Gaining insights into the strategic value of COVID-19, the
CPC Central Committee places people’s life and health in
priority. Upon the outbreak of the pandemic, China has made
concerted efforts by making full use of all available resources
and intensified the investment in vaccine R&D. China has
launched a state-level vaccine reserve project and promised
to make COVID-19 vaccines global public products, which
offers COVID-19 vaccine producers ample market space.
(2) The deployment is scientific and adopts parallel lines.
The Research Group for Joint Prevention and Control of
COVID-19 under the State Council (hereafter referred to as
the Research Group) treated vaccine R&D as its prioritized
task. Through screening, it confirmed the synchronous
promotion of the R&D in inactivated vaccines, adenovirus

vector vaccines, recombinant protein vaccines, vaccines
using attenuated influenza virus as vectors, nuclear acid
vaccine. The links and stages of vaccine R&D which used to
be in series are now in parallel, which greatly shortens the
needed time.
(3) Resources of all parties are organized to form joint
forces. Under the leadership of the CPC Central Committee,
the Research Group coordinates the vaccine R&D process.
Relevant departments work together to ensure that science
and technology resources, policy examination and approval,
and materials are available to meet the needs of key tasks. ①
Vaccine R&D. The forces of research institutions, medical
institutions, and enterprises are assembled to integrate laboratory R&D, animal experiments, pilot scale production,
and clinical trials. ② Vaccine production. China simultaneously promotes R&D and production. Multi-departments
work together to speed up the examination and approval of
the facility construction for vaccine production, strengthen
vaccine production scheduling, and expedite enterprises’
productivity building, so as to stabilize production, industrial
chain, and supply chain in preparation for large-scale production. ③ Vaccine evaluation and approval. China innovates vaccine evaluation and approval patterns. Regulators
step in early to guarantee interconnection between vaccine
R&D and approval. The government, research institutions,
approval authorities, and enterprises coordinate with each
other to maximize the efficiency and success rate of vaccine
R&D. R&D is a long-term process, in which universities,
research institutions, and enterprises draw on each other’s
strengths.

2.2 Universities, research institutions, and enterprises draw on each other’s strengths in the
long-term R&D
China’s success in the rapid development of COVID-19
vaccines is attributed to its long-term independent innovation
in bio-medicine. The long-term development of science and
technology lays a foundation for the successful R&D of
COVID-19 vaccines. Moreover, it underpins the development of China’s strategic science and technology forces.
(1) China’s innovative R&D capacity of vaccines has improved significantly. China has greatly improved its innovation capacity for vaccine R&D owing to the state’s years’
support for science and technology development, especially
the major project “Key Technology for Vaccine Research and
Development and Product Development” under National
High-tech R&D Program (863 Program), National Science
and Technology Major Projects “Prevention and Treatment of
Serious Infectious Diseases such as AIDS and Viral Hepatitis”
and “Formulation of Major New Medicines”, and National
Key R&D Program “Research and Development of Key
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Technology for Biological Security.” China is the first to
succeed in developing recombinant hepatitis E vaccine, inactivated enterovirus 71 vaccine, recombinant Ebola virus
vaccine, achieving good social benefits and economic efficiency. China’s experience in technology development, talent
training and reserve, platform establishment and development, research team building in its fight against bird flu and
H1N1 influenza has laid a solid foundation for China’s R&D
of COVID-19 vaccines.
(2) China’s strategic science and technology forces play an
important role in emergency response. The 12 COVID-19
vaccine R&D teams selected by the Research Group are
mostly the national strategic science and technology forces
long supported by national science and technology programs.
① Research institutions serve as the backbone. The CAS, the
Academy of Military Medical Sciences, the Chinese Academy of Medical Sciences and many other research institutions provide general technological support through
multidisciplinary platforms such as virus isolation, antigen
design, animal modeling, in vivo and in vitro evaluation, and
quality evaluation. The rapid application of research results
to vaccine R&D has enabled China to spearhead the R&D of
COVID-19 vaccines around the world. ② Major science and
technology enterprises play a key role. Vaccine producers
with rich R&D experience and complete technology industrialization platforms have made great contributions. With
their own superiority in technology or production, these enterprises invest in advance in vaccine R&D and expand their
production capacity during the pandemic. They shoulder their
due corporate social responsibilities.
(3) Universities, research institutions, and enterprises
collaborate to draw on each other’s strengths. An important
approach to the R&D of COVID-19 vaccines is to enhance
the cooperation between universities, research institutions,
and enterprises. Such cooperation can break the “last-mile”
bottleneck of industrialized R&D of COVID-19 vaccine.
Thus, it shapes a seamless joint pattern, in which the government steers the direction, national strategic science and
technology forces act the main players, and enterprises are
ready to approach government, universities, and institutions.
Successful cases include but are not limited to the followings.
The Academy of Military Medical Sciences and CanSinoBIO, based on their long-term cooperation, have jointly developed adenovirus vector vaccines, which is the first
COVID-19 vaccine entering the clinical stage. The CAS and
Anhui Zhifei Longcom Biopharmaceutical Co. Ltd jointly
developed a recombinant COVID-19 vaccine, which is the
first recombinant protein vaccine against COVID-19 approved for use in the world.

2.3

Demand-driven and objective-oriented R&D

The COVID-19 vaccine R&D aims to meet national major
strategic demands. It encompasses basic research, key
common technologies, and production. China has developed
a successful paradigm for COVID-19 vaccine R&D, which is

demand-driven and objective-oriented. Such paradigm sparks
ideas for building up national strategic science and technology forces.
The COVID-19 vaccine R&D embodies the evolution and
development of Pasteur’s quadrant theory in China which
pools its resources to realize the goal. To control the pandemic of COVID-19, China rallies all its forces to focus on
prevention and control technology and vaccine R&D. In the
course, China identifies problems and develops new understandings. New insights drive China to tackle strangling
problems in vaccine R&D to address critical issues in prevention and control technology and products.
(1) Immediately identifying COVID-19 vaccine application as the research objective. First, China confirms applicable COVID-19 vaccine types and reachable capacity. Second,
top-level design and decomposed deployment are put in
place. ① To maximize the success of COVID-19 vaccine
R&D, China sets in advance multiple technological routes in
parallel and promoted a holistic R&D strategy. In light of the
success possibility of different technological routes and
China’s domestic existing conditions, China finalized five
major technological routes, and supported a total of 12 research teams for emergency research. ② In line with reachable capacity and institution–enterprise integration principle,
China initiated, in advance, production facility construction,
trial production, and raw material reserve to guarantee
productivity expansion.
(2) Spotting new science-related issues in the COVID-19
vaccine R&D. Aiming at antigen design, efficacy and safety
evaluation of candidate vaccines, process development,
quality control and verification, clinical trials and large-scale
production, the Research Group dynamically track and collect the feedback data to punctually spot the science-related
issues to be urgently addressed. Is the choice of COVID-19
vaccine antigens immunogenic and specific enough to handle
viral mutations, and to elicit durable immune response? In
terms of vaccine safety evaluation, will candidate COVID-19
vaccines cause acute toxicity and repeated toxicity, and how
can we predict and prevent the antibody-dependent enhancement (ADE) of COVID-19 vaccines? In terms of vaccine efficacy evaluation in clinical trials, how can human
responses be better predicted via animal models? Are humoral and cellular immunity stimulated by COVID-19 vaccines equally important? And is it possible to establish
surrogate endpoints for COVID-19 vaccine efficacy
evaluation?
(3) Concentrating efforts and resources to tackle critical
problems. Having identified science problems, the research
teams conducted research centered on the screening and
optimization of antigen and the prediction of ADE. On one
hand, to address these science problems, we need to further
improve basic research of virology, immunology, and vaccinology. On the other hand, solving these problems will not
only support the optimization and innovation of COVID-19
vaccines but also provide new targets for the development of
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antivirals and new ideas for blocking the spread of the virus.

3 Reflection on China’s strategic science and
technology forces
The R&D of COVID-19 vaccine sheds new light on the
building of China’s strategic science and technology forces.
The 19th National Congress of the CPC, and the Fourth and
Fifth Plenary Sessions of the 19th CPC Central Committee
have made an overall action plan for strengthening national
strategic science and technology forces. It has become an
extremely important task for building China’s science and
technology innovation system. To this end, we need to explore the organization mode, function positioning, and operation mechanism.

3.1 Mission positioning: combination of long-term
and emergency missions
China’s experience in the prevention and control of
COVID-19 shows that a country should make forwardlooking technological deployment in advance, accumulate
adequate research experience, build up technological reserve,
and set definite national science and technology positioning
and fully-fledged emergency response mechanism. To accurately position national strategic science and technology
forces, we must take into account both long-term effect and
the need for emergency. For one thing, we must ensure that
the positioning is visionary, lasts long, and can produce a
permanent effect. For another thing, it should meet the demand, especially emergency and even potential risks. We
must make discipline, domain, and territory arrangement
conform to the country’s medium-to-long-term planning. We
encourage original innovation to underpin China’s efforts to
build itself into a strong country to lead science and technology in the future. Supported by strong R&D and industrialization capacity, we should maximize strong points and
give full play to grouping competitiveness to gear to the need
of national major strategies. We should bring science and
technology into play to deal with “black swan” and “grey
rhino” events.

3.2 Top-level design for regular and emergency
purposes
To organize and motivate quality forces from across the
country for science and technology innovation in pandemic
prevention and control, the Research Group sets a special
group responsible for virus isolation, animal experiment,
product preparation, and clinical research. China’s promotion
of COVID-19 vaccine R&D observes the laws of science.
The special group for vaccine R&D is a well-coordinated
measure in response to emergency. It is only through close
and effective coordination that national strategic science and

technology forces from different domains can pool resources
to accomplish sizable tasks. Such coordination mechanism
should serve both emergent and regular purposes under the
guidance of relevant governmental authorities.
In case of no emergency, we should observe the laws of
science. Considering the major tasks and goals of science and
technology innovation, we should make continuous efforts
for technological reserve and talent building in a regular
manner. We must foster national strategic science and technology forces through institutionalization. Meanwhile, we
should, step by step, set up a regular coordination mechanism
to improve the research team and capacity building to guard
ourselves against public health emergencies.

3.3 Strengthening methods: with focus on both
reorganization and empowerment
In terms of current policy design and practice, reorganization and empowerment are two effective paths available.
Sticking to the principle of inheriting fine tradition and
seeking innovation, we should handle well the relations between reorganization and empowerment, as well as between
increment and stock in organizational structure and developmental mechanism. (1) Ensuring quality and increment
through reorganization. Various innovation players should be
organically regrouped in biological technology and life science which are interdisciplinary, intensive, and collaborative
to enable state-level labs and large-scale innovation enterprises to break new ground and achieve new inventions. (2)
Invigorating key science and technology forces. Taking into
account the big picture of a national innovation system, we
must coordinate science and technology innovation forces,
improve element allocation, and systematically build a talent
group for state-level science institutes and major universities to
enable them to make fresh contributions and accomplishments.

4

Policy suggestions

The world is undergoing profound changes unseen in a
century. We must take into full account the profound adjustment of international competition in economy as well as
science and technology, and seize the strategic opportunity of
a new round of scientific and industrial revolution. We should
uphold Xi Jinping’s Thought on Socialism with Chinese
Characteristics for a New Era as the theoretical and practical
guidance. Efforts should be made to improve the top-level
design for national strategic science and technology forces
and the innovation ecology. It is suggested to sharpen the
competitiveness of national strategic science and technology
forces through original innovation. Such initiative is driven
by national major tasks and demands. We must make good
use of the new system concentrating nationwide efforts and
resources on key undertakings to reinforce national strategic
science and technology forces.
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4.1 Systematic deployment and forward-looking
planning
(1) Strategically valuing top-level design. ① In terms of
strategic direction, we must give full play to the role of the
state in organizing major science and technology innovations.
All we do must aim to meet the strategic demand of national
major strategies and put people’s life and health on the top
position. ② The endeavor needs to be driven by well-defined
strategic tasks geared to global advance level, economic
development, national major demand, and people’s life and
health. We set biotechnology and life and health as the new
orientations and focuses of innovation. Priority should be
given to addressing critical problems limiting science development and national security. ③ We should continue to
build high-level R&D platforms. Relying on research institutions, universities, and key enterprises, we should
strengthen the construction of new R&D institutions in the
basic, frontier, emerging, crossing, marginal disciplines, and
weak and vacant disciplines of life sciences and biotechnology, and focus on cultivating the reserve team of national key
laboratories in these fields. ④ In terms of team building, we
will steadily support a number of research teams shouldering
the national missions, and introduce and cultivate top-notch
scholars and innovative teams meeting the standard of national strategic science and technology forces. We should
improve the assessment and evaluation system, which should
uphold research quality and academic contribution and focus
on the originality, contribution, and impact of research
achievements.
(2) Dual-wheel driving tactic. According to the development trend of global life and health, we should maintain
strategic focus and vision, and adhere to the dual-wheel drive
of technological innovation and institutional innovation. The
allocation of resources and the layout of innovation factors
should be optimized. Specifically, resources in key technology areas to be prioritized should be concentrated to highlight
competitive advantages. We should strengthen the coordination of national strategic technological forces and market
players to accelerate the transfer and transformation of
technological achievements and facilitate the key links of the
innovation value chain.

4.2

Far vision and pragmatic attitude

(1) Conducting in-depth basic and applied research geared
to the need of the future. We should support autonomous
basic research and establish a stable support initiative that
conforms to the law of basic research. The top teams of national strategic technology forces should be given strong and
stable support as well as complementary services to engage in
research in a worry-free environment. We should enhance our
financial support for basic research, forward-looking and
non-consensus research to foster disruptive innovations.
(2) Reinforcing national strategic science and technology
forces in practice to meet the current demand. Driven by

national major demands and significant science and technology tasks, we should provide practical opportunities to
strengthen national strategic science and technology forces.
By giving full play to state labs, state key labs, regional
innovation centers, and science and technology enterprises,
which serve as the vehicle of national strategic science and
technology forces, we should manage to integrate multiple
disciplines and gather top talents at home and abroad to
tackle major science issues and core technology. In practice,
state-level R&D forces oriented to the future are gradually
fostered through an organization system.
(3) Strengthening national strategic science and technology forces by utilizing global innovation resources. While
adhering to Chinese characteristics, we should integrate
ourselves into the global innovation system. We should grow
ourselves into a key node in the innovation network and make
good use of global innovation resources to build up national
strategic science and technology forces. State-level science
institutions are expected to open posts to talents from across
the world. We encourage high-caliber science researchers to
serve important posts in international organizations to participate in global governance and international standard
formulation in science and technology.

4.3 Building an innovation system to provide
wide-ranging services
(1) Integrating the new system concentrating nationwide
efforts and resources on key undertakings into the building of
national strategic science and technology forces by providing
governmental innovation services. National science and
technology departments in charge should endeavor to scale
up innovation services. Governmental services should be an
element of national strategic science and technology forces.
Science management agencies shall play a role in resource
integration and organization coordination. We must make
sure that the organization and implementation of major science tasks should meet the need of the country and manifest
state will.
(2) Realizing resource sharing by building strategic innovation resource reserve and public technology platforms.
Efforts should be made to build bases that are for public good,
shared, and open, such as platforms for laboratory animal and
diseased animal models, standard and evaluation platforms,
and state-level biology information center. It is recommended
to strategically deploy animal resource, microorganism resource, and human heredity resource reserves. To improve
science resource allocation and sharing, we must first guarantee resource supply for national strategic science and
technology forces.
(3) Accelerating the commercialization of achievements to
optimize innovation ecology. We should regulate the coordinated innovation mechanism for promoting cooperation,
establish an active science operation and mobilization
mechanism, and set up a supporting system in place. The
connection of supervision, access, application institutions
with science innovation should be stressed to smooth the
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chain of policy. A sound supporting institution favorable for
talent initiatives, finance and taxation should be built to create the innovation ecology conducive to the commercialization of innovation achievements.

References
1 Bai C L. Strengthen national strategic science and technology forces. The
People’s Congress of China, 2021, (7): 29–31. (in Chinese)

2 Hu Y L. Fighting unknown through collaboration: Establishment of national strategy for vaccine production stockpile. Chinese Public Administration, 2020, (5): 26–31. (in Chinese)
3 Zhang J X. What makes China a leader of COVID-19 vaccine research and
development. Science and Technology Daily, 2020–07–07(08). (in Chinese)
4 Hu Y L. What contributes to China as a global leader in the research and
development of COVID-19 vaccine. Guangming Daily, 2021–01–07(16).
(in Chinese)
(Translated by WEN JX)

ZHANG Xinmin Director of China National Center for Biotechnology Development, Ministry of
Science and Technology, Doctor of Engineering, Researcher. He mainly carries out strategic research
and policy analysis in the field of biotechnology in China, participates in the formulation of national
science and technology plans such as “2021–2035 National Medium- and Long-term Science and
Technology Development Plan” and “14th Five-Year Plan for Science and Technology Innovation”,
and organizes the implementation of national science and technology plans in the field of biotechnology. E-mail: zhangxm@cncbd.org.cn

© 2021 China Academic Journals (CD Edition) Electronic Publishing House Co., Ltd.

6

